186 related articles for article (PubMed ID: 37196196)
21. An
Han Y; Wong FC; Wang D; Kahlert C
Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
[TBL] [Abstract][Full Text] [Related]
22. Machine Learning of Histopathological Images Predicts Recurrences of Resected Pancreatic Ductal Adenocarcinoma With Adjuvant Treatment.
Yamaguchi R; Morikawa H; Akatsuka J; Numata Y; Noguchi A; Kokumai T; Ishida M; Mizuma M; Nakagawa K; Unno M; Miyake A; Tamiya G; Yamamoto Y; Furukawa T
Pancreas; 2024 Feb; 53(2):e199-e204. PubMed ID: 38127849
[TBL] [Abstract][Full Text] [Related]
23. Expression of cytokeratin-20 in pancreatic cancer: an indicator of poor outcome after R0 resection.
Schmitz-Winnenthal FH; Volk C; Helmke B; Berger S; Hinz U; Koch M; Weitz J; Kleeff J; Friess H; Zöller M; Büchler MW; Z'graggen K
Surgery; 2006 Jan; 139(1):104-8. PubMed ID: 16364723
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
25. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
26. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma.
Nishiwada S; Cui Y; Sho M; Jun E; Akahori T; Nakamura K; Sonohara F; Yamada S; Fujii T; Han IW; Tsai S; Kodera Y; Park JO; Von Hoff D; Kim SC; Li W; Goel A
Ann Surg; 2022 Dec; 276(6):e876-e885. PubMed ID: 34132691
[TBL] [Abstract][Full Text] [Related]
27. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K; Hablesreiter R; Inoue Y; Yoshida K; Briest F; Christen F; Kakiuchi N; Yoshizato T; Shiozawa Y; Shiraishi Y; Striefler JK; Bischoff S; Lohneis P; Putter H; Blau O; Keilholz U; Bullinger L; Pelzer U; Hummel M; Riess H; Ogawa S; Sinn M; Damm F
EBioMedicine; 2021 Apr; 66():103327. PubMed ID: 33862582
[TBL] [Abstract][Full Text] [Related]
28. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
29. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.
Maire F; Hammel P; Terris B; Paye F; Scoazec JY; Cellier C; Barthet M; O'Toole D; Rufat P; Partensky C; Cuillerier E; Lévy P; Belghiti J; Ruszniewski P
Gut; 2002 Nov; 51(5):717-22. PubMed ID: 12377813
[TBL] [Abstract][Full Text] [Related]
31. Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning.
Yokoyama S; Hamada T; Higashi M; Matsuo K; Maemura K; Kurahara H; Horinouchi M; Hiraki T; Sugimoto T; Akahane T; Yonezawa S; Kornmann M; Batra SK; Hollingsworth MA; Tanimoto A
Clin Cancer Res; 2020 May; 26(10):2411-2421. PubMed ID: 31992588
[TBL] [Abstract][Full Text] [Related]
32. A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
Gao Z; Han H; Zhao Y; Yuan H; Zheng S; Zhang Y; Chen H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3195-3209. PubMed ID: 34291356
[TBL] [Abstract][Full Text] [Related]
33. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection.
Zhang LP; Ren H; Du YX; Wang CF
World J Gastroenterol; 2020 Dec; 26(46):7382-7404. PubMed ID: 33362391
[TBL] [Abstract][Full Text] [Related]
35. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
36. Diffusion-weighted MR imaging in pancreatic ductal adenocarcinoma: prediction of next-generation sequencing-based tumor cellularity and prognosis after surgical resection.
Jeon SK; Jang JY; Kwon W; Kim H; Han Y; Kim D; Park D; Kim JH
Abdom Radiol (NY); 2021 Oct; 46(10):4787-4799. PubMed ID: 34143259
[TBL] [Abstract][Full Text] [Related]
37. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.
van Roessel S; Kasumova GG; Verheij J; Najarian RM; Maggino L; de Pastena M; Malleo G; Marchegiani G; Salvia R; Ng SC; de Geus SW; Lof S; Giovinazzo F; van Dam JL; Kent TS; Busch OR; van Eijck CH; Koerkamp BG; Abu Hilal M; Bassi C; Tseng JF; Besselink MG
JAMA Surg; 2018 Dec; 153(12):e183617. PubMed ID: 30285076
[TBL] [Abstract][Full Text] [Related]
38. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma.
Feng Z; Shi M; Li K; Ma Y; Jiang L; Chen H; Peng C
J Transl Med; 2020 Sep; 18(1):360. PubMed ID: 32958051
[TBL] [Abstract][Full Text] [Related]
40. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
